Transmembrane peptide-loaded ionic liquid nanocarriers for targeting ErbB2-positive cancer

06 November 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The transmembrane peptide domains (TMs) of membrane proteins are involved in signal transduction and are crucial for receptor dimerization. Human epidermal growth factor receptor 2 (HER2 or ErbB2) promotes accelerated cancer cell proliferation and survival and is overexpressed in over 20% of all malignancies. We target ErbB2 in a set of ErbB2-positive cancer cell lines by chemically synthesized peptides mimicking the full ErbB2 TM, which inhibited downstream MAPK and PI3K/Akt signaling and drastically reduced cell viability. Loading the ErbB2 TM into surface-active ionic liquid nanocarriers demonstrated a synergic effect on cell viability via cell membrane disruption with simultaneous inhibition of the downstream signaling cascades. Thus, this proof-of-concept study demonstrates TM peptides in conjunction with surface-active ionic liquid carriers as a promising strategy for targeted cancer treatment and broad application, exemplified on ErbB2 receptor as a target here.

Keywords

transmembrane peptide
cancer
epidermal growth factor receptor
ionic liquid
nanocarrier

Supplementary materials

Title
Description
Actions
Title
Supplementary information
Description
additional tables and figures
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.